Q32 Bio (QTTB) shares surged over 100% after striking a $592 million deal with Akebia Therapeutics for its Phase complement inhibitor, ADX-097. The agreement validates QTTB’s platform and provides immediate cash flow, but the stock’s rapid rise raises valuation concerns and execution risks. Wall Street remains optimistic, rating QTTB a “Moderate Buy” with a target price of $12.

Read more at Yahoo Finance: This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?